Purpose: Data comparing the long-term efficacy and safety of subcutaneous immunotherapy (SCIT) using house dust mite (HDM) in children and adults with allergic rhinitis (AR) are limited. This study aimed to compare the long-term effects of HDM-SCIT in a cohort of Chinese pediatric and adult patients with AR. Methods: A total of 124 pediatric and adult AR patients received HDM-SCIT for 3 years, with 118 patients being followed-up for 2 years. Prior to treatment (baseline), at the end of the 3-year treatment periods (third year) and 2 years after the discontinuation of treatment (fifth year), all patients were evaluated for total nasal symptom scores (TNSS), daily medication score (DMS), total combined score (TCS; symptoms [nasal + ocular] + DMS) and quality of life (QoL). Safety was assessed according to adverse events reported. Results: After 3-year treatment, HDM-SCIT significantly improved symptoms and QoL scores at the end of the third and fifth years in both groups. Better improvements were observed in the third and fifth years based on baseline, in children compared to adults (TNSS Delta 3: 6.66 vs. 5.41, P = 0.011; TCS Delta 3: 4.30 vs. 3.83, P = 0.027 and TNSS Delta 5: 6.16 vs. 4.86, P = 0.037; TCS Delta 5: 4.11 vs. 3.62, P = 0.044). Shorter duration of AR history before SCIT (<10 vs. >= 10 years) resulted in better improvements at the end of the third and fifth years (TCS Delta 3: 4.12 vs. 3.13, P = 0.036; TCS Delta 5: 3.90 vs. 3.09, P = 0.033). HDM-SCIT was safe and comparable in both children and adults with AR. Conclusions: Children with AR may achieve better long-term efficacy of HDM-SCIT than adults with AR.
基金：
national natural science foundation of ChinaNational Natural Science Foundation of China (NSFC) [81630023, 81420108009, 81400444, 81470678]; Program for Changjiang Scholars and Innovative Research TeamProgram for Changjiang Scholars & Innovative Research Team in University (PCSIRT) [IRT13082]; Beijing Municipal Administration of Hospitals' Mission Plan [SML20150203]; Beijing Municipal Administration of Hospitals' Youth Programme [QML20150202]; Beijing Natural Science FoundationBeijing Natural Science Foundation [Z141107002514122]; Capital Health Development Foundation [2016-1-2052]; Beijing Advanced Innovation Center for Food Nutrition and Human Health, Beijing Technology and Business University (BTBU) [20181045]
第一作者机构：[1]Capital Med Univ, Beijing TongRen Hosp, Dept Otolaryngol Head & Neck Surg, 1 Dongjiaominxiang, Beijing 100730, Peoples R China[2]Beijing Inst Otolaryngol, Beijing Key Lab Nasal Dis, 17 Hougou Hutong, Beijing 100005, Peoples R China
共同第一作者：
通讯作者：
通讯机构：[1]Capital Med Univ, Beijing TongRen Hosp, Dept Otolaryngol Head & Neck Surg, 1 Dongjiaominxiang, Beijing 100730, Peoples R China[2]Beijing Inst Otolaryngol, Beijing Key Lab Nasal Dis, 17 Hougou Hutong, Beijing 100005, Peoples R China[3]Capital Med Univ, Beijing TongRen Hosp, Dept Allergy, Beijing, Peoples R China[*1]Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, No. 1, Dongjiaominxiang, Dongcheng Distrct, Beijing 100730, China[*2]Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, No. 1, Dongjiaominxiang, Dongcheng Distrct, Beijing 100730, China
推荐引用方式(GB/T 7714)：
Huang Yanran,Wang Chengshuo,Cao Feifei,et al.Comparison of Long-term Efficacy of Subcutaneous Immunotherapy in Pediatric and Adult Patients With Allergic Rhinitis[J].ALLERGY ASTHMA & IMMUNOLOGY RESEARCH.2019,11(1):68-78.doi:10.4168/aair.2019.11.1.68.
APA：
Huang, Yanran,Wang, Chengshuo,Cao, Feifei,Zhao, Yan,Lou, Hongfei&Zhang, Luo.(2019).Comparison of Long-term Efficacy of Subcutaneous Immunotherapy in Pediatric and Adult Patients With Allergic Rhinitis.ALLERGY ASTHMA & IMMUNOLOGY RESEARCH,11,(1)
MLA：
Huang, Yanran,et al."Comparison of Long-term Efficacy of Subcutaneous Immunotherapy in Pediatric and Adult Patients With Allergic Rhinitis".ALLERGY ASTHMA & IMMUNOLOGY RESEARCH 11..1(2019):68-78
